AionWell’s current priority applications are precision oncology, radiopharmaceutical research, and targeted therapeutic development with biomarker and molecular validation. Aging biology and geroscience are a long-term scientific focus, labelled as emerging.
Biological insight Decision-ready evidence
Application — Current Priority
Precision Oncology
Molecular targets, therapeutic evaluation, biomarkers, and preclinical research — disease-relevant target biology, antibody-based research, biomarker evaluation, and suitable preclinical imaging.
Application — Current Priority
Radiopharmaceutical Research
Molecular probes, radiolabeling, biodistribution, and quantitative imaging — evidence for targeted radiopharmaceutical development, without implying clinical manufacturing or approved diagnostic capability.
Across Capabilities
Targeted Therapeutics and Biomarkers
Research tools and experimental approaches supporting biological characterization and candidate evaluation — delivered through the translational evidence, molecular research, and imaging capabilities rather than a separate service line.
Application — Emerging Focus
Aging Biology and Geroscience
An emerging scientific focus on age-related disease mechanisms, cellular health, and potential translational research applications — a long-term direction, not a validated service portfolio.
Working in one of these areas?
Tell us about your scientific objective and the decision it supports.